July 2020 tender notification

Medicines

Tender Closed

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018 and the 2019/20 Invitation to Tender, dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:

  • For new listings, by 4pm on 12 August 2020 or the 5th of the month prior to listing, whichever is earlier
  • For price changes, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. 

More information about this process and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link)  and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or the new listing date above (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

Download the Tender results

2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand
(Supplier)

Date of subsidy change

Sole Subsidised Supply date

Hydrocortisone

Crm 1%;
500 g Jar

$17.15

$17.15

Hydrocortisone (PSM)
(API Consumer Brands)

1 September 2020

1 December 2020

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Hydrocortisone

Crm 1%;
500 g Jar

$17.15

$17.15

Hydrocortisone (PSM)
(API Consumer Brands)

1%

1 September 2020

1 December 2020

2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand
(Supplier)

Date of subsidy change

Sole Subsidised Supply date

Bupropion hydrochloride

Tab modified-release 150 mg;
30 tablet blister pack

$11.00

$11.00

Zyban
(GlaxoSmithKline NZ Limited)

1 December 2020

1 March 2021

Cyproterone acetate with ethinyloestradiol

Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs;
168 tablet blister pack

$4.67

$4.98

Ginet
(Rex Medical Ltd)

1 January 2021

1 April 2021

Losartan potassium

Tab 12.5 mg;
84 tablet blister pack

$1.39

$1.56

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1 October 2020

1 January 2021

Losartan potassium

Tab 25 mg;
84 tablet blister pack

$1.63

$1.84

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1 October 2020

1 January 2021

Losartan potassium

Tab 50 mg;
84 tablet blister pack

$2.00

$2.25

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1 October 2020

1 January 2021

Losartan potassium

Tab 100 mg;
84 tablet blister pack

$2.31

$3.50

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1 October 2020

1 January 2021

Naltrexone hydrochloride

Tab 50 mg;
30 tablet blister pack

$112.55

$133.33

Naltraccord
(Teva Pharma Australia Pty Ltd)

1 October 2020

1 January 2021

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand (Supplier)

Date of listing

Sole Subsidised Supply date

Brand (Supplier) affected by delisting

Goserelin

Implant 3.6 mg, syringe;
1 prefilled syringe pack

$66.48

$65.68

Goserelin-Teva
(Teva Pharma Australia Pty Ltd)

1 December 2020

1 May 2021

Zoladex
(AstraZeneca)

Goserelin

Implant 10.8 mg, syringe;
1 prefilled syringe pack

$177.50

$122.37

Goserelin-Teva
(Teva Pharma Australia Pty Ltd)

1 December 2020

1 May 2021

Zoladex
(AstraZeneca)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Bupropion hydrochloride

Tab modified-release 150 mg;
30 tablet blister pack

$11.00

$11.00

Zyban
(GlaxoSmithKline NZ Limited)

1%

1 December 2020

1 March 2021

Cyproterone acetate with ethinyloestradiol

Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs;
168 tablet blister pack

$4.67

$4.98

Ginet
(Rex Medical Ltd)

1%

1 January 2021

1 April 2021

Losartan potassium

Tab 12.5 mg;
84 tablet blister pack

$1.39

$1.56

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1%

1 October 2020

1 January 2021

Losartan potassium

Tab 25 mg;
84 tablet blister pack

$1.63

$1.84

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1%

1 October 2020

1 January 2021

Losartan potassium

Tab 50 mg;
84 tablet blister pack

$2.00

$2.25

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1%

1 October 2020

1 January 2021

Losartan potassium

Tab 100 mg;
84 tablet blister pack

$2.31

$3.50

Losartan Actavis
(Teva Pharma Australia Pty Ltd)

1%

1 October 2020

1 January 2021

Naltrexone hydrochloride

Tab 50 mg;
30 tablet blister pack

$112.55

$133.33

Naltraccord
(Teva Pharma Australia Pty Ltd)

1%

1 October 2020

1 January 2021

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Hospital supply brand (Supplier)

DV Limit

Listing date

Hospital Supply Status date

Brand (Supplier) affected by delisting

Goserelin

Implant 3.6 mg, syringe;

1 prefilled syringe pack

$66.48

$65.68

Goserelin-Teva
(Teva)

1%

1 December 2020

1 May 2021

Zoladex
(AstraZeneca)

Goserelin

Implant 10.8 mg, syringe;

1 prefilled syringe pack

$177.50

$122.37

Goserelin-Teva
(Teva)

1%

1 December 2020

1 May 2021

Zoladex
(AstraZeneca)

Metronidazole

Inj 5 mg per ml, 100 ml bag;
10 bag pack

$55.00

$27.50

Baxter
(Baxter Healthcare Ltd)

1%

1 September 2020

1 February 2021

AFT (bottle)
(AFT);
Colpocin-T (bottle)
(Multichem)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2018/19 Invitation to Tender, dated 1 November 2018, and
  • the 2019/20 Invitation to Tender, dated 1 November 2019.

2018/19 Invitation to Tender

Chemical name

Line item

Adapalene

Crm 0.1%

Adapalene

Gel 0.1%

Amoxicillin clavulanate

Inj 500 mg with clavulanic acid 100 mg

Amoxicillin clavulanate

Inj 1000 mg with clavulanic acid 200 mg

Beclomethasone dipropionate

Metered aqueous nasal spray, 50 mcg per dose

Beclomethasone dipropionate

Metered aqueous nasal spray, 100 mcg per dose

Bupivacaine hydrochloride with glucose

Inj 0.5% with glucose, 4 ml ampoule

Fentanyl

Inj 20 mcg per ml, 100 ml bag

Fentanyl

Inj 10 mcg per ml, 50 ml prefilled syringe

Fentanyl

Inj 10 mcg per ml, 10 ml syringe

Ganciclovir

Inj 500 mg

Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet

Minocycline hydrochloride

Cap 100 mg

Pemetrexed

Powder for infusion, 500 mg

Sodium citrate

Oral liq 8.8% (300 mmol/l)

2019/20 Invitation to Tender

Chemical name

Line item

Carvedilol

Tab 6.25 mg

Carvedilol

Tab 12.5 mg

Carvedilol

Tab 25 mg

Diclofenac sodium

Inj 25 mg per ml, 3 ml

Ibuprofen

Tab 200 mg

Glyceryl trinitrate

Spray 400 mcg per dose

Lacosamide (current access)

Inj 10 mg per ml, 20 ml

Lacosamide (current access)

Tab 50 mg

Lacosamide (current access)

Tab 100 mg

Lacosamide (current access)

Tab 150 mg

Lacosamide (current access)

Tab 200 mg

Lacosamide (widened access)

Tab 50 mg

Lacosamide (widened access)

Tab 100 mg

Lacosamide (widened access)

Tab 150 mg

Lacosamide (widened access)

Tab 200 mg

Oestradiol

Tab 1 mg

Oestradiol

Tab 2 mg

Oestradiol

TDDS 25 mcg per day

Oestradiol

TDDS 50 mcg per day

Oestradiol

TDDS 75 mcg per day

Oestradiol

TDDS 100 mcg per day

Oestradiol with norethisterone

Tab 1 mg with 0.5 mg norethisterone acetate

Oestradiol with norethisterone

Tab 2 mg with 1 mg norethisterone acetate

Oestradiol with norethisterone

Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg (oestradiol tab (12) and 1 mg oestradiol tab (6)

For products included in the 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.